ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
March 14 2024 - 7:57AM
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for the treatment of inflammatory and renal diseases with
high unmet medical needs, announces that Stephen C. Glover,
Co-Founder, Chairman, Chief Executive Officer, and President, will
participate in a panel discussion titled “Inflammation
Illuminated,” at Benzinga’s Virtual Healthcare Summit 2024. During
the discussion, Mr. Glover will talk about a protein complex
discovered around 15 years ago, called inflammasome, and how it
triggers the development and spread of damaging inflammation that
is the culprit behind many of our most deadly diseases. He will
also address new innovations in drug development to alleviate
damaging inflammation.
Details regarding Mr. Glover’s panel discussion are
as follows:
Event: |
Benzinga’s Virtual Healthcare Summit 2024 |
Date: |
Wednesday, March 20, 2024 |
Time: |
1:30 to 2:00pm EDT |
Registration: |
https://www.benzinga.com/events/virtual-healthcare-summit-2024/ |
|
About Inflammasome ASC Inhibitor IC
100
IC 100 is a novel humanized IgG4 monoclonal
antibody that inhibits the inflammasome adaptor protein ASC. IC 100
was designed to attenuate both initiation and perpetuation of the
inflammatory response. It does so by binding to a specific region
of the ASC component of multiple types of inflammasomes, including
NLRP1, NLRP3, and AIM2, to address inflammatory diseases in which
multiple inflammasome pathways are activated. Intracellularly, IC
100 binds to ASC monomers, inhibiting inflammasome formation,
thereby blocking activation of IL-1β early in the inflammatory
cascade. IC 100 also binds to ASC in ASC Specks, both
intracellularly and extracellularly, further blocking activation of
IL-1β and the spread and perpetuation of the inflammatory response
that is pathogenic in inflammatory diseases. Because active
cytokines amplify adaptive immunity through various mechanisms, IC
100, by attenuating cytokine activation, also attenuates the
adaptive immune response. To review a white paper summarizing the
mechanism of action and preclinical data for IC 100, Click
Here.
About ZyVersa Therapeutics,
Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage
specialty biopharmaceutical company leveraging advanced,
proprietary technologies to develop first-in-class drugs for
patients with renal and inflammatory diseases who have significant
unmet medical needs. The Company is currently advancing a
therapeutic development pipeline with multiple programs built
around its two proprietary technologies – Cholesterol Efflux
Mediator™ VAR 200 for treatment of kidney diseases, and
Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation
associated with numerous CNS and peripheral inflammatory diseases.
For more information, please visit
www.zyversa.com.
Cautionary Statement Regarding
Forward-Looking Statements
Certain statements contained in this press release
regarding matters that are not historical facts, are
forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended, and the Private
Securities Litigation Reform Act of 1995. These include statements
regarding management’s intentions, plans, beliefs, expectations, or
forecasts for the future, and, therefore, you are cautioned not to
place undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not
possible for ZyVersa to predict all such factors, nor can ZyVersa
assess the impact of each such factor on the business or the extent
to which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any
forward-looking statements. Forward-looking statements included in
this press release are based on information available to ZyVersa as
of the date of this press release. ZyVersa disclaims any obligation
to update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to
sell, or the solicitation of an offer to buy, any securities.
Corporate, Media, and IR
Contact:Karen CashmereChief Commercial
Officerkcashmere@zyversa.com786-251-9641
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Sep 2024 to Oct 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Oct 2023 to Oct 2024